Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial.
Shankar Siva, Mathias Bressel, Simon Wood, Mark Shaw, Sherene Loi, Shahneen Sandhu, Ben Tran, Arun Azad, Jeremy Lewin, Katharine Cuff, Nitika Neha, Duncan Colyer, Paul J. Neeson, Howard Liu, Sarat Chander, Daniel Moon, Jeremy Goad, Declan G. Murphy, Nathan Lawrentschuk, David Pryor (2021). Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial.. , 39(6_suppl), DOI: https://doi.org/10.1200/jco.2021.39.6_suppl.277.
Article155 days agoStereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial
Shankar Siva, Mathias Bressel, Simon Wood, Mark Shaw, Sherene Loi, Shahneen Sandhu, Ben Tran, Arun Azad, Jeremy Lewin, Katharine Cuff, Howard Liu, Daniel Moon, Jeremy Goad, Lih‐Ming Wong, Michael Lim‐Joon, Jennifer Mooi, Sarat Chander, Declan G. Murphy, Nathan Lawrentschuk, David Pryor (2021). Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial. , 81(4), DOI: https://doi.org/10.1016/j.eururo.2021.12.006.
Article155 days agoA phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol
David Pryor, Mathias Bressel, Nathan Lawrentschuk, Ben Tran, Jennifer Mooi, Jeremy Lewin, Arun Azad, Duncan Colyer, Nitika Neha, Mark Shaw, Sarat Chander, Paul J. Neeson, Daniel Moon, Katharine Cuff, Simon Wood, Declan G. Murphy, Shahneen Sandhu, Sherene Loi, Shankar Siva (2021). A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol. , 21, DOI: https://doi.org/10.1016/j.conctc.2021.100703.
Article155 days agoThe RAPPORT clinical trial: interim safety analysis of combination SABR with adjuvant anti-PD1 immunotherapy in oligometastatic renal cell carcinoma
Shankar Siva, Mathias Bressel, Mark Shaw, Sarat Chander, Sherene Loi, David Pryor, Shahneen Sandhu, Jennifer Mooi, Dasantha Jayamanne, Thomas Eade, Nathan Lawrentschuk, Declan Murphy, Jeremy Lewin, Ben Tran, Farshad Foroudi (2018). The RAPPORT clinical trial: interim safety analysis of combination SABR with adjuvant anti-PD1 immunotherapy in oligometastatic renal cell carcinoma.
Article155 days agoThe RAPPORT clinical trial: interim safety analysis of combination SABR with adjuvant anti-PD1 immunotherapy in oligometastatic renal cell carcinoma
Shankar Siva, Mathias Bressel, Mark Shaw, Sarat Chander, Sherene Loi, David Pryor, Shahneen Sandhu, Jennifer Mooi, Dasantha Jayamanne, Thomas Eade, Nathan Lawrentschuk, Declan Murphy, Jeremy Lewin, Ben Tran, Farshad Foroudi (2018). The RAPPORT clinical trial: interim safety analysis of combination SABR with adjuvant anti-PD1 immunotherapy in oligometastatic renal cell carcinoma.
Article155 days ago